Every material Form 8-K Immix Biopharma, Inc. has filed with the SEC since July 20, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Immix Biopharma agreed on September 29, 2026 to sell 11,363,637 shares of common stock at $11.00 per share in an underwritten offering led by J.P. Morgan Securities LLC. The company expects gross proceeds of $125 million and net proceeds of approximately $117.1 million, with closing expected on September 30, 2026. The company plans to use the proceeds for NXC-201 development, working capital and general corporate purposes.
11,363,637 shares priced at $11.00 per share under an underwriting agreement with J.P. Morgan Securities LLC dated September 29, 2026
Expected gross proceeds of $125 million and net proceeds of approximately $117.1 million after underwriting discounts, commissions and offering expenses
Offering expected to close on or about September 30, 2026, subject to customary conditions; proceeds to fund NXC-201 development, working capital and general corporate purposes
Immix Biopharma said an interim update from its Phase 2 NEXICART-2 trial shows an 89% (40/45) complete response rate across all 45 enrolled relapsed/refractory AL Amyloidosis patients, as assessed by an independent review committee. The company said the final readout and BLA submission are planned for mid-2027, so the data remain interim and the therapy has not been approved.
Complete response rate of 89% (40/45) across all 45 enrolled patients, per an independent review committee
All 25 new patients are in complete response or MRD-negative (21 in CR, 4 MRD-negative)
Four MRD-negative patients still pending; the company says this could raise the CR rate to up to 98% (44/45)
Final readout and BLA submission planned for mid-2027; company reported no neurotoxicity or enterocolitis to date
Immix Biopharma disclosed that Richard Graydon was terminated and is no longer with the company as of July 17, 2026, for reasons it says are unrelated to his activities at the company. Management believes that, given his short tenure, the departure has no material effect on the business. The filing does not state Graydon's role or give any financial figures.
Termination effective as of July 17, 2026
Company says the reasons are unrelated to Graydon's activities at the company
Management believes there is no material effect on the business given his short tenure
Filing dated July 20, 2026, signed by CEO Ilya Rachman, M.D., Ph.D.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Immix Biopharma, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →